The scientist’s investigation covers issues in Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy. His research links Gastroenterology with Internal medicine. His Oncology research incorporates themes from Paclitaxel, Tumor-infiltrating lymphocytes, Proportional hazards model, Docetaxel and Biomarker.
His Breast cancer research includes elements of Adjuvant, Clinical trial and Metastasis. His biological study spans a wide range of topics, including Cohort and Rituximab. His work deals with themes such as Anthracycline, Regimen, Recurrence score, Molecular diagnostic techniques and Estrogen Metabolism, which intersect with Chemotherapy.
His primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery. Joseph A. Sparano works mostly in the field of Oncology, limiting it down to topics relating to Rituximab and, in certain cases, CHOP and Non-Hodgkin's lymphoma.
His Breast cancer study integrates concerns from other disciplines, such as Cancer research, Disease, Docetaxel and Hazard ratio. His research in Cancer intersects with topics in Gynecology and Pathology. His Chemotherapy study frequently draws connections between adjacent fields such as Regimen.
Joseph A. Sparano mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. His research in Metastatic breast cancer, Hazard ratio, Clinical trial, Chemotherapy regimen and Neutropenia are components of Internal medicine. His research on Oncology also deals with topics like
Joseph A. Sparano has included themes like Stage, Metastasis and Proportional hazards model in his Breast cancer study. His work deals with themes such as Biomarker, Eribulin, Paclitaxel and Doxorubicin, which intersect with Metastasis. His study looks at the intersection of Chemotherapy and topics like Prospective cohort study with Adjuvant.
Joseph A. Sparano focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer. His studies in Cyclophosphamide, Disease, Young adult, Adjuvant and Prospective cohort study are all subfields of Internal medicine research. His Oncology study combines topics in areas such as Clinical trial, Metastatic breast cancer, Metastasis, Biomarker and Radiation therapy.
Joseph A. Sparano combines subjects such as Stage, Proportional hazards model and Hazard ratio with his study of Breast cancer. His studies deal with areas such as Pertuzumab, Neoadjuvant therapy and Trastuzumab emtansine as well as Chemotherapy. His work in Cancer addresses subjects such as Immunosuppression, which are connected to disciplines such as Lung cancer, Case fatality rate, Multivariate analysis, Malignancy and Anal cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado;C. Denkert;S. Demaria;N. Sirtaine.
Annals of Oncology (2015)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard.
The New England Journal of Medicine (2018)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams;Robert J. Gray;Sandra Demaria;Lori Goldstein.
Journal of Clinical Oncology (2014)
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Joseph A. Sparano;Joseph A. Sparano;Molin Wang;Silvana Martino;Vicky Jones.
The New England Journal of Medicine (2008)
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
Clifford A. Hudis;William E. Barlow;Joseph P. Costantino;Robert J. Gray.
Journal of Clinical Oncology (2007)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
J. Bergh;K. Pritchard;K. Albain;S. Anderson.
The Lancet (2015)
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Joseph A. Sparano;Soonmyung Paik.
Journal of Clinical Oncology (2008)
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.
Vikas Mehta;Sanjay Goel;Rafi Kabarriti;Daniel Cole.
Cancer Discovery (2020)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh.
Lancet Oncology (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: